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C BY-NC-NAbstract An efﬁcient and facile method for the synthesis of novel structurally diverse b-amino
dicarbonyl compounds is described by exploring the aza-Michael addition reaction in an aqueous
medium as a key step. Thereby, 2-(aryl-disubstituted-amino-1-yl-methyl)-malonic acid diethyl esters
were achieved in a good to excellent yields. These products were easily isolated with enough purity
just by using simple recrystallization. The crystals of the compounds (17) and (24) have been
obtained and studied by X-ray crystallographic analyses.
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D license.1. Introduction
The HIV-1 Integrase (HI) is a valid target for chemotherapeu-
tic intervention due to its involvement in the viral replication
process (Goldgur et al., 1999; Walker et al., 2007; Gopi
et al., 2009). The chemical inhibition of HI could be reached
via intermolecular coordination between HI/chemical inhibi-
tor/metals (Mg2+ and Mn2+, co-factors of the HI), leading
to the formation of bimetallic complexes (Lebon et al., 2002;
Dayam et al., 2007; Dayam and Neamati, 2004; Sechi et al.,
2009; Zenga et al., 2008). In fact, the most successful strategy
to inhibit the HI is to explore the structural core of b-diketo
acid type, as brieﬂy illustrated in Fig. 1 (Sorrell et al., 1991;
Bacchi et al., 2008; Sechi et al., 2006; Orvig and Abrams,
1999). In view of this, it is highly desirable to obtain the im-




































Figure 1 Some of the HIV inhibitors under clinical trials or those (I and Elviltegavir) were recently approved by US FDA.
162 I. Meskini et al.For the preparation of such polydentate ligands, the aza-
Michael addition seems to be a key-step (Hayashi et al.,
1996). Among the large number of unconventional methodol-
ogies, this kind of reaction has widely been employed to gener-
ate structurally diverse b-amino dicarbonyl compounds (Zhu
et al., 2009; Kumar et al., 2008). Most of these unconventional
methodologies have used Lewis acids, which although leading
to satisfactory yields but it still requires the alternatives (Basu
et al., 2004; Wabnitz and Spencer, 2002). Moreover, the use of
an aqueous medium (Ranu and Banerjee, 2007; Ranu and
Mandal, 2007; Ranu et al., 2005) has been a successful source
in achieving expected results in better yield with greener touch
eliminating the use of hazardous solvents. Usually, these types
of substrates are less reactive or conversely more resistant to
undergo the Michael addition which results in low conversion
of the desired adducts. From the synthetic point of view, this is
a considerable limitation on the Michael reaction process and
poses a signiﬁcant challenge.
To this end, we decided to investigate the feasibility of
applying the aza-Michael reactions to the more challenging
substituted alkene derivatives. Our idea is to explore the appli-
cation of this key-step to the synthesis of a set of polydentate
O,O,N-ligands (Scheme 1), in order to highlight the versatility
of the procedure as well as to generate some insights regarding
the 3D crystalline structure of two compounds (17) and (24).
2. Chemistry
Our synthetic strategy is very clear. In the ﬁrst step, 2-arylid-
ene-malonic acid ethyl esters (1)–(13) were prepared by the
condensation of substituted arylaldehydes with diethyl-malon-
ate in ethanol under reﬂux condition, using piperazine and gla-
cial acetic acid as a catalyst. This procedure furnished the
intermediates, 2-arylidene-malonic acid ethyl esters (1)–(13),
quickly and in excellent yields (Scheme 1).
To further explore the scope and limitations of the aza-Mi-
chael reaction, compound (1) was chosen as the model precur-
sor because of its thermo stability and also due to the less
reactivity of pyrazole towards traditional aza-Michael addi-
tion. It was found that the stirring of compound (1) and pyr-
azole together in water at room temperature for 12 h led to
the formation of 71% of (15) (Scheme 2). During the investiga-
tion of experimental conditions, it was possible to observe that
the acid catalyst (AcOH, 0.1 mol%) accelerates the reaction
but it is not essential (Meskini et al., 2010a,b,c).Having well established and developed reaction conditions,
it was identiﬁed that precursors (1)–(13) reacted quickly; with
various secondary amines under catalyst-free conditions to
provide the desired adducts (14)–(35) in good to excellent
yields. These products were characterized using spectroscopic
(1H and 13C NMR, IR and MS) and micro-analytical data.
The compounds (14)–(35) are insoluble in water. The com-
pound (16) has been recrystallized from ethanol to obtain the
single suitable crystal and studied by X-ray diffraction study
(Meskini et al., 2010a,b,c). Since, NaOH is a strong base there-
fore it is likely that the compounds are saponiﬁed into carbox-
ylate units upon dissolution to form substituted b-amino
dicarboxylates of sodium. However, we were unable to obtain
the hypothetical bimetallic species by conventional means. The
attempts to crystallise the substituted b-amino dicarboxylate
derivative of (16) resulted in crystallisation of a polymeric
complex; the poly[[bis{l3-2-[(3,5-dimethyl-1H-pyrazol-1-
yl)(phenyl)methyl]propanedioato}tetrasodium](I) 7.5-hydrate]
(160) (Scheme 3). The compound (160) has been used then in
our laboratory as a starting material in organometallic chem-
istry and surprisingly its coordination mode has not been re-
ported previously in literature. Since it is such an important
precursor its structure will be brieﬂy described here (Fig. 2).
The coordination of Cu(NO3)2Æ2H2O to b-amino dicarbox-
ylate ligands (14)–(35) in basic medium led us to obtain bime-
tallic complexes (Scheme 4 and Fig. 3).
3. Results and discussion
In order to get more insight into the theoretically possible
points of metallic coordination, we have aimed to replace the
phenyl by 4-chloro-phenyl, 4-methyl-phenyl or triﬂuoro-
methyl-phenyl fragments (Scheme 2).
Analyzing the X-ray crystallography data (Figs. 4 and 5), it
has revealed that the crystal is subject of a weak torsion
around the C1–C2 bond, of dihedral angle [N(1), C(1), C(2),
H(2)] equal to 68.04(2). The nitrogen atom N(1) is trivalent
with N(1)–C(1), N(1)–C(15) and N(1)–C(22) bonds of
1.484(1), 1.473(2) and 1.471(2) A˚, respectively; they do not re-
main trans, indicating a cis 1,2-addition. Conﬁrmation of the
cis-addition is also indicated by the ORTEP of compound
(24) in which it is easy to see the dihedral angle [N(1), C(1),
C(2), H(2)] in the same range. This observed geometric form
was conﬁrmed by studying the crystallographic features for
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Scheme 1 Synthetic protocol for the generation of aminodicarbonyl precursors (1)–(13).
Synthesis, characterization and coordination chemistry of substituted b-amino dicarbonyls 163The solid state structures for (17) and (24) (Figs. 4 and 5)
were in full agreement with the proposed one than in solution
(see Table 1).
4. Experimental protocols
4.1. Materials and methods
Infrared spectra were recorded on a PYE Unicam SP3-300
spectrometer as KBr pellets. The 1H and 13C NMR spectra
were recorded on Bruker spectrometer (250 and 400 MHz)
using TMS as internal standard. Chemical shifts are reported
downﬁeld from the standard in ppm. The FAB mass spectra
were obtained on a NERMANG R10-LOC instrument. For
the chemical ionisation (DCI/NH3/CH3), the compounds were
dissolved in DMSO or MeOH and dispersed in a matrix solu-
tion, currently the 3-nitrobenzyl (MNBA) or glycerol (GLY).
Elemental analyses were performed (Morocco). All common
laboratory chemicals were purchased from commercial sources
and used without further puriﬁcation.4.2. General procedure for the synthesis of intermediates (1)–
(13)
To a solution of ethyl malonate (15 g, 93 mmol) in 40 mL of
ethanol, were added the respective aldehyde (100 mmol), fol-
lowed by the addition of 1.5 mL of piperidine and 1 mL of gla-
cial acetic acid. The reaction mixture was then stirred at reﬂux
temperature of ethanol for 12 h, until thin-layer chromatogra-
phy indicated the complete consumption of the starting mate-
rial. After removing the solvent under vacuum, the crude
product was washed with a saturated solution of sodium bisul-
ﬁte (20 mL). The product was extracted by diethyl ether
(2 · 20 mL), dried with sodium sulphate and evaporated to
give the respective pure yellow oils for (1–3, 6, 7) and micro-
crystals or white powder for (4, 5, 8–13).
4.2.1. 2-Benzylidene-malonic acid diethyl ester (1)
Yield: 71%; Rf = 0.7 (ether/hexane: 1/1); IR (KBr, m cm
1):
2875–2982 (CH), 1722 (C‚O), 1629–1497 (C‚C), 1294–
1254 (C–O); 1H NMR (300 MHz, CDCl3) d ppm: 7.72 (s,
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Scheme 3 Polymerization of (16) to produce poly[[bis{l3-2-[(3,5-dimethyl-1H-pyrazol-1-yl)(phenyl)methyl]propanedioato}tetrasodi-
um](I) 7.5-hydrate] (160).
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Scheme 4 Synthetic protocol for the generation of bimetallic compound (36).
Figure 3 Ortep of the complex Cu2(CH3COO
)4(H2O)2 (36). Figure 4 ORTEP drawing of compound (17).
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Figure 5 ORTEP drawing of compound (24).
Table 1 Crystallographic data for compounds (17) and (24).




Space group P-1 P-1
a (A˚) 7.9880 (3) 8.4744 (3)
b (A˚) 10.9559 (4) 11.1119 (4)
c (A˚) 14.8493 (7) 13.2992 (4)
a () 77.269 (4) 70.866 (3)
b () 85.682 (4) 77.862 (3)
c () 68.709 (4) 71.331 (3)
Z 2 2
k(Mo-Ka) (A˚) 0.71069 0.71073
l (mm1) 0.083 0.199
T (K) 110 110
h, k, lmax 10, 13, 18 10, 14, 16
hmax 27.000 27.000
R1[I> 2p(I)], all data 0.0376 (3467) 0.0314 (3751)
wR2[I> 2p(I)], all data 0.0900 (5108) 0.0889 (4836)
CCDC number 734201 734199
166 I. Meskini et al.1H, C‚CH–Ph), 7.45–7.32 (m, 5H, Ph), 4.32 (q, 2H, 2OCH2–
CH3,
3J= 7.2 Hz), 4.28 (q, 2H, 2OCH2–CH3,
3J= 7.2 Hz),
1.31 (t, 3H, 2OCH2CH3,
3J= 7.1 Hz), 1.25 (t, 3H,
2OCH2CH3,
3J= 7.1 Hz); 13C NMR (300 MHz, CDCl3) d
ppm: 166.6–166.2 (2C‚O), 142.0 (PhCH), 132.8 (Cquat, Ph),
130.5 (2Ctert,meta), 129.4 (Ctert,para), 128.7 (2Ctert,ortho), 126.1
(Cquat, ‚C), 61.6–61.6 (2C, 2OCH2CH3), 14.1–13.8 (2C,
2OCH2CH3); SM (IE): Calc. for C14H16O4: 248; [M+H]
+
(m/z) = 249 (100%).
4.2.2. 2-(4-Chlorobenzylidene)-malonic acid diethyl ester (2)
Yield: 77%; Rf = 0.73 (ether/hexane: 1/1); IR (KBr, m cm
1):
2906–2982 (CH), 1724 (C‚O), 1591–1631 (C‚C), 1254–
1308 (C–O); 1H NMR (300 MHz, CDCl3) d ppm: 7.7 (s, 1H,C‚CH–Ph), 7.45–7.30 (m, 4H, Ph), 4.31–4.4 (2q, 4H,
2OCH2CH3,
3J= 7.12 Hz), 1.31–1.25 (2t, 6H, 2OCH2CH3,
3J= 7.11 Hz); 13C NMR (300 MHz, CDCl3) d ppm: 166.3–
163.8 (2C‚O), 140.0 (ClPh–CH‚C), 132.9 (Cquat, C–Cl–
Ph), 130.3 (2Cmeta), 130.4 (Cquat, para/Cl), 129.0 (2Cortho),
125.4 (C‚C–(CO2Et)2), 61.4 and 61.7 (2OCH2CH3), 13.7
and 13.8 (2OCH2CH3); SM (IE): Calc. for C14H15ClO4:
282.07; [M+H]+ (m/z) = 283 (100%).
4.2.3. 2-(4-Methoxybenzylidene)-malonic acid diethyl ester (3)
Yield: 66%; Rf = 0.71 (ether/hexane: 1/1); IR (KBr, m cm
1):
2840–2982 (CH), 1725 (C‚O), 1512–1574 (C‚C), 1253–
1305 (C–O), 1170, 1118, 892.416; 1H NMR (300 MHz, CDCl3)
d ppm: 7.7 (s, 1H, C‚CH–Ph), 6.90–7.40 (m, 4H, arom), 4.20–
4.30 (2q, 4H, 2OCH2–CH3,
3J= 7.15 Hz), 1.30–1.40 (2t, 6H,
2OCH2CH3,
3J= 7.14 Hz); 13C NMR (300 MHz, CDCl3) d
ppm: 165–161.57 (2C‚O), 141.79 (–CH‚), 182 (–Cquat, C–
OCH3–Ph), 131.59 (2Cmeta, arom), 127 (Cquat, para/OCH3),
130.87 (2Cortho, arom), 125.41 (‚C–(CO2Et)2), 61.63–61.45
(2CH2–CH3), 13.97–14.06 (2OCH3CH2), 3.23 (s, 3H, OCH3–
Ph).
4.2.4. 2-(4-Dimethylaminobenzylidene)-malonic acid diethyl
ester (4)
Yield: 83%; Rf = 0.24 (ether/hexane: 1/1); mp: 120 C; IR
(KBr, m cm1): 2905–2987 (CH), 1721 (C‚O), 1582–1527
(C‚C), 1298–1318 (C–O), 1226, 1113, 727, 419; 1H NMR
(300 MHz, CDCl3) d ppm: 7.62 (s, 1H, C‚CH–Ph), 6.61 (d,
2H, arom), 7.34 (d, 2H, arom), 4.20–4.30 (2q, 4H, 2OCH2CH3,
3J= 7.18 Hz), 1.29–1.30 (2t, 6H, 2OCH2CH3,
3J= 7.17 Hz);
13C NMR (300 MHz, CDCl3) d ppm: 165.05–167.93
(2C‚O), 142.63 (–CH‚C), 151 (Cquat, C–N(CH3)2–Ph),
111.54 (2Cmeta, arom), 120.15 (Cquat, para/N(CH3)2), 131.88
(2Cortho, arom), 119.97 (C‚C–(CO2Et)2), 61.35–61.03
(2OCH2CH3), 14.27–14.54 (2OCH3CH2).
4.2.5. 2-(4-Nitrobenzylidene)-malonic acid diethyl ester (5)
Yield: 45%; Rf = 0.22 (ether/hexane: 1/1); mp: 168 C; IR
(KBr, m cm1): 2852–2988 (CH), 1713 (C‚O), 1492–1518
(C‚C), 1250–1299 (C–O), 1199, 1063, 748, 412; 1H NMR
(300 MHz, CDCl3) d ppm: 7.7 (s, 1H, C‚CH–Ph), 8.3 (d,
2H, arom), 7.8 (d, 2H, arom), 4.3–4.40 (2q, 4H, 2OCH2CH3),
1.2–1.30 (2t, 6H, 2OCH2CH3);
13C NMR (300 MHz, CDCl3) d
ppm: 166.26–165.2 (2C‚O), 138.78 (Ph–CH‚C), 205 (–Cquat,
C–NO2–Ph), 123 (2Cmeta, arom), 120.15 (Cquat, para/
N(CH3)2), 130.26 (2Cortho, arom), 130 (‚C–(CO2Et)2), 61.62
(C, 2OCH2CH3), 13.25–14.45 (C, 2OCH3CH2).
4.2.6. 2-(4-Methylbenzylidene)-malonic acid diethyl ester (6)
Yield: 76%; Rf = 0.67 (ether/hexane: 1/1); IR (KBr, m cm
1):
2906–2982 (CH), 1723 (C‚O), 1590–1632 (C‚C), 1254–
1308 (C–O); 1H NMR (300 MHz, CDCl3) d ppm: 7.7 (s, 1H,
C‚CH–Ph), 7.17–7.20 (d, 2H, Ph, 3J= 8.1 Hz), 7.35–7.37
(d, 2H, Ph, 3J= 8.1 Hz), 4.27–4.39 (2q, 4H, 2OCH2CH3,
3J= 7.12 Hz), 1.29–1.36 (2t, 6H, 2OCH2CH3,
3J= 7.19 Hz),
2.25 (s, 3H, CH3–Ph);
13C NMR (300 MHz, CDCl3) d ppm:
166.95–163.8 (2C‚O), 142.15 (CH3–Ph–CH‚), 141.16 (Cquat,
CCH3Ph), 129.55 (2Cmeta), 130.1 (Cquat, para/CH3), 129.58
(2Cortho), 125.19 (C‚C–(CO2Et)2), 61.6–61.5 (2OCH2CH3),
21.4 (CH3Ph); 14.1–13.9 (2OCH2CH3); SM (IE): Calc. for
[M]+ C15H18O4: 262.04. [M+H]
+ (m/z) = 263 (100%).
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ester (7)
Yield: 77%; Rf = 0.81 (ether/hexane: 1/1); IR (KBr, m cm
1):
2905–2987 (CH), 1728 (C‚O), 1593–1631 (C‚C), 1252–
1312 (C–O); 1H NMR (300 MHz, CDCl3) d ppm: 7.57 (s,
1H, C‚CHPh), 7.53–7.50 (d, 2Hortho, Ph,
3J= 9 Hz), 7.47–
7.44 (d, 2Hmeta, Ph,
3J= 9 Hz), 4.27–4.31 (2q, 4H,
2OCH2CH3,
3J= 7.19 Hz), 1.28–1.31 (2t, 6H, 2OCH2CH3,
3J= 7.19 Hz); 13C NMR (3000 MHz, CDCl3) d ppm:
165.88–163.52 (2C‚O), 140.05 (CF3PhCH‚), 136.46 (Cquat,
CF3Ph), 129.07 (2Cmeta), 131.01 (Cquat, para/CF3), 129.82
(2Cortho), 125.92 (C‚C(CO2Et)2), 61.81–61.57 (2OCH2CH3),
77.52 (CF3Ph), 13.51–13.61 (2OCH3CH2); SM (IE): Calc. for
[M]+ C15H15O4F3: 316.02. [M+H]
+ (m/z) = 317 (100%).
4.2.8. Ethyl 2-cyano-3-phenylacrylate (E) (8)
Yield: 80%; Rf = 0.64 (ether/hexane: 1/1); mp: 91 C; IR
(KBr, m cm1): 2900–3068 (CH), 1721.76 (C‚O), 1605–1443
(C‚C), 1252–1292 (C–O); 1H NMR (300 MHz, CDCl3) d
ppm: 8.22 (s, 1H, C‚CH–Ph), 7.47–7.79 (m, 5H, Ph), 4.33–
4.4 (2q, 2OCH2CH3,
3J= 7.2 Hz), 1.35–1.40 (2t, 2OCH2CH3,
3J= 7.1 Hz); 13C NMR (300 MHz, CDCl3) d ppm: 162.39
(C‚O), 154.93 (Ph–CH‚C), 115.44 (C‚N), 131.48 (Cquat,
Ph), 133.27 (2C tert,meta), 131.03 (C tert,para), 129.26 (2C ter-
t,ortho), 103.06 (Cquat, ‚C(CO2Et)), 62.68 (C, OCH2CH3),
14.14 (C, OCH2CH3).
4.2.9. Ethyl 2-cyano-3-(4-chlorophenyl) acrylate (E) (9)
Yield: 86%; Rf = 0.72 (ether/hexane: 1/1); mp: 125 C; IR
(KBr, m cm1): 2893–3024 (CH); 1724.24 (C‚O), 1598–1467
(C‚C), 1248–1311 (C–O); 1H NMR (300 MHz, CDCl3) d
ppm: 8.21 (s, 1H, C‚CH–Ph), 7.16–8.05 (m, 4H, Ph), 4.33–
4.40 (q, 2H, OCH2CH3,
3J= 7.20 Hz), 1.35 (t, 3H,
OCH2CH3,
3J= 7.20 Hz); 13C NMR (300 MHz, CDCl3) d
ppm: 162.38 (C‚O), 153.49 (Cl–Ph–CH‚C), 115.45
(C‚N), 127.87 (Cquat, C–Cl–Ph), 133.54 (2Cmeta), 133.66
(Cquat, para/Cl), 116.85 (2Cortho), 102.54 (C‚C–(CO2Et)),
62.79 (OCH2CH3), 14.15 (OCH2CH3).
4.2.10. Ethyl 2-cyano-3-(4-methoxyphenyl) acrylate (E) (10)
Yield: 83%; Rf = 0.63 (ether/hexane: 1/1); mp: 114 C; 1H
NMR (300 MHz, CDCl3) d ppm: 8.18 (s, 1H, C‚CH–Ph),
7.33–8.03 (m, 4H, Ph), 4.2–4.46 (q, 2H, OCH2CH3,
3J= 7.20 Hz), 2.35 (s, 3H, CH3–OPh), 1.35–1.41 (2t, 6H,
2CH2–CH3,
3J= 7.20 Hz); 13C NMR (300 MHz, CDCl3) d
ppm: 163.33 (C‚O), 154.25 (CH3O–Ph–CH‚C), 115.45
(C‚N), 127.87 (Cquat, –CH3–OCPh), 132.43 (2Cmeta), 131.86
(Cquat, para/OCH3), 119.41 (2Cortho), 101.83 (C‚C–(CO2Et)),
61.42 (OCH2CH3), 14.03 (OCH2–CH3).
4.2.11. Ethyl 2-cyano-3-(4-dimethylaminophenyl)acrylate
(E) (11)
Yield: 94%; Rf = 0.75 (ether/hexane: 1/1); mp: 93 C; IR
(KBr, m cm1): 2832–2936 (CH), 1702 (C‚O), 1565–1610
(C‚C), 1271–1296 (C–O); 1H NMR (300 MHz, CDCl3) d
ppm: 8.08 (s, 1H, C‚CH–Ph), 6.69–7.96 (m, 4H, Ph), 4.31–
4.38 (q, 2H, OCH2CH3,
3J= 7.20 Hz), 3.11 (s, 6H,
N(CH3)2), 1.36–1.41 (2t, 3H, OCH2CH3,
3J= 7.20 Hz); 13C
NMR (300 MHz, CDCl3) d ppm: 164.26 (C‚O), 154.50
(NMe2–Ph–CH‚), 117.53 (C‚N), 154.11 (Cquat, NMe2–Ph),
111.50 (2Cmeta), 119.42 (Cquat, para/NMe2), 134.02 (2Cortho),
94.16 (C‚C–(CO2Et)), 61.85 (OCH2–CH3), 39.98 (CH3–NPh) 14.28 (OCH2CH3); SM(IE): C14H16O2N2: [M]
+ (m/z)
= 244 (100%).
4.2.12. Ethyl 2-cyano-3-(4-methylphenyl)acrylate (E) (12)
Yield: 88%; Rf = 0.61 (ether/hexane: 1/1); mp: 112 C; 1H
NMR (300 MHz, CDCl3) d ppm: 8.23 (s, 1H, C‚CH–Ph),
2.45 (s, 3H, CH3–Ph), 7.28–7.93 (m, 4H, Ph), 4.35–4.43 (q,
2H, 2OCH2CH3,
3J= 7.20 Hz), 1.38–1.43 (2t, 6H,
2OCH2CH3,
3J= 7.20 Hz); 13C NMR (300 MHz, CDCl3) d
ppm: 162.78 (C‚O), 154.99 (pCH3–Ph–CH‚), 115.78
(C‚N), 128.90 (Cquat, C–pCH3–Ph), 130.04 (2Cmeta), 131.26
(Cquat, para/CH3), 130.04 (2Cortho), 101.61 (C‚C–(CO2Et)),
62.59 (OCH2–CH3), 14.18 (OCH2CH3), 21.87 (CH3–Ph); SM
(IE): C13H13O2N: [M]
+ (m/z) = 215 (100%). [MOEt]+ (m/
z) = 170.
4.2.13. Ethyl 2-cyano-3-(4-ﬂurophenyl)acrylate (E) (13)
Yield: 64%; Rf = 0.73 (ether/hexane: 1/1); mp: 123 C; IR
(KBr, m cm1): 2900–3068 (CH), 1721 (C‚O), 1572–1605
(C‚C), 1252–1299 (C–O); 1H NMR (300 MHz, CDCl3) d
ppm: 8.25 (s, 1H, C‚CH–Ph), 7.46–7.96 (m, 4H, Ph), 4.36–
4.43 (q, 2H, OCH2CH3,
3J= 7.20 Hz), 1.39–1.43 (2t, 6H,
2OCH2CH3,
3J= 6.90 Hz); 13C NMR (300 MHz, CDCl3) d
ppm: 162.22 (C‚O), 153.36 (p-F–Ph–CH‚C), 115.25
(C‚N), 139.58 (Cquat, –F–CPh), 129.68 (2Cmeta), 129.90
(Cquat, para/F), 132.19 (2Cortho), 103.5 (C‚C–(CO2Et)),
62.86 (OCH2CH3), 14.14 (OCH2CH3).
4.3. General procedure for the synthesis of compounds
(14)–(35)
To a solution of the substituted 2-arylidenemalonic acid
diethyl esters (1)–(13) (5 mmol) in water (25 mL) was added
(6 mmol) of the respective secondary amines (morpholine;
3,5-dimethyl-1H-pyrazole; 4-bromo-3,5-dimethyl-pyrazole;
piperidine; pyrolydene; pyrazole; ethylbenzylamine; dibenzyl-
amine and methylbenzylamine) in the presence or absence of
acetic acid (0.1 mol%) and the stirring was continued at room
temperature until the complete consumption of the starting
material as indicated by TLC. After removing solvent, the
crude products were dissolved in diethyl ether (2 · 20 mL)
and washed with water until the pH became neutral. The or-
ganic solvent was dried over sodium sulphate and then evapo-
rated to give the respective yellow oils which then puriﬁed by
recrystallisation in (hexane/ether: 2/1) mixture. We have ob-
tained pure compounds as white crystals (14)–(35).
4.3.1. 2-[(Phenyl)-piperidin-1-yl-methyl]-malonic acid diethyl
ester (14)
White crystals; Yield: 80%; Rf = 0.72 (ether/hexane: 1/1); mp:
68 C; IR (KBr, m cm1): 2848–2974 (C–H, Ph), 2754–2800 (C–
H, aliph), 1702–1740 (C‚O), 1514–1450 (C‚C), 1313–1257
(C–O); 1H NMR (300 MHz, CDCl3) d ppm: 1.00 (t, 3H,
OCH2CH3,
3J= 7.1 Hz), 1.26 (m, 2H, –C3
0
H2–, pr), 1.35 (t,
3H, OCH2CH3,
3J= 7.1 Hz), 1.50 (m, 4H, 2C2
0
H2, pr), 2.20
(s large, 2H, C1
0
H2, pr), 2.59 (s large, 2H, C
10H2, pr), 4.02
(dq, 2HAB, O–CH2–CH3,
2JA–B = 10.7 Hz,
3J= 6.9 Hz),
4.23 (d, 1H, C2H–(CO2Et)2,
3J= 12.1 Hz), 4.33 (dq, 2H,
OCH2CH3, JA–B = 0.2 Hz,
3J= 7.1 Hz), 4.43 (d, 1H, Ph–
C3H, 3J= 12 Hz), 7.15–7.34 (m, 5H, Ph); 13C NMR
(300 MHz, CDCl3) d ppm: 167.22–168.04 (2C‚O), 133.93
(Cquat, Ph), 128.69 (2Ctert,ortho, Ph), 127.80 (Ctert,para, Ph),
168 I. Meskini et al.127.53 (2Ctert,meta, Ph), 69.15 (Ctert, PhC
2H), 61.30–61.15 (2C,
2OCH2CH3), 54.96 (Ctert, C
2H(CO2Et)2), 50.55 (2C, 2C
10H2,
pr), 26.50 (2C, 2C2
0
H2, pr), 24.40 (C, C
30H2, pr), 14.30–13.75
(2C, 2OCH2CH3); SM (IE): [M]
+ C19H27NO4: 333.19;
[M+H]+ (m/z) = 334 (35%); 174 (100%); Element. analysis:
Calc. C19H27NO4: %C= 68.46 ; %H= 8.40; %N= 4.20.
Found: %C= 67.89; %H= 7.89; %N= 4.22.
4.3.2. 2-(Phenyl-pyrazol-1-yl-methyl)-malonic acid diethyl (15)
White crystals; Yield: 76%; Rf = 0.45 (ether/hexane: 1/1); mp:
89 C; IR (KBr, m cm1): 2896–2985 (CH), 1748 (C‚O), 1514–
1595 (C‚C), 1292–1308 (C–O), 1175, 1139, 1013, 866, 753,
440; 1H NMR (300 MHz, CDCl3) d ppm: 7.30–7.46 (m, 4H,
aromat, 3J= 8.35 Hz), 6.20 (t, 1H, C4
0





HPz, 3J= 14.4 Hz), 5.85 (d, 1H, PhC3H,
3J= 11.36 Hz), 4.80 (d, 1H, C2H(CO2Et)2,
3J= 11.11 Hz),
3.95 (dq, 2HAB, OCH2CH3, JAB = 14.30 Hz,
3J= 7.11 Hz),
4.12 (dq, 2HAB, OCH2CH3, JAB = 14.30 Hz,
3J= 7.11 Hz),
1.15 (t, 3H, OCH2CH3,
3J= 7.13 Hz), 1.01 (t, 3H, OCH2CH3,
3J= 7.13 Hz); 13C NMR (300 MHz, CDCl3) d ppm: 166.37
(C‚O), 166.61 (C‚O), 137.15 (Cquat, Ph), 128.62 (Ctert, 2Cme-
ta/arm, Ph), 129.76 (Ctert, 2Cortho/arm, Ph), 139.56 (Ctert, C
50–
Pz), 128.67 (Ctert, C
300–Pz), 105.71 (Ctert, C
4H, Pz), 61.87–
61.76 (Csec, 2CH2, ester), 64.22 (Ctert, C
3HPh), 57.33 (Ctert,
C2H(CO2Et)2), 13.87 (C, OCH2CH3), 13.69 (C, OCH2CH3);
SM (IE): [M]+ C17H20O4: 316, 35; [M+H]
+ (m/z) = 317,
[MCH(CO2Et)2]+ (m/z) = 157 (100%); Element. analysis:
Calc. C17H20O4: %C= 64.54; %H= 6.37; %N= 8.8.
Found: %C= 67.37; %H= 6.34; %N= 8.56.
4.3.3. 2-[(Phenyl)-(3,5-dimethyl-pyrazol-1-yl)-methyl]-
malonic acid diethyl ester (16)
White crystals; Yield: 76%; Rf = 0.69 (ether/hexane: 1/1); mp:
88 C; IR (KBr, m cm1): 2868–2974 (C–H), 1747–1719
(C‚O), 1586–1554 (C‚C), 1460–1419 (C‚N), 1269–1264
(C–O); 1H NMR (300 MHz, CDCl3) d ppm: 7.45–7.25 (m,
5H, Ph), 5.78 (d, 1H, Ph–C3H, 3J= 11.2 Hz), 5.74 (s, 1H,
H4
0
, Pz), 4.9 (d, 1H, PhC3HC2H, 3J= 11.4 Hz), 4.16–3.99
(2q, 2H, OCH2CH3,
3J= 7.3 Hz), 3.97 (q, 2H, OCH2CH3,
3J= 7.1 Hz), 2.25 (s, 1H, C3
0
H3, Pz), 2.21 (s, 1H, C
50H3, Pz),
1.17 (t, 3H, OCH2CH3,
3J= 7.1 Hz), 0.98 (t, 3H, OCH2CH3,
3J= 7.1 Hz); 13C NMR (300 MHz, CDCl3) d ppm: 166.90–
166.85 (2C‚O), 147.3 (Cquat, C
50, Pz), 139.30 (Cquat, Ph),
137.30 (Cquat, C
30, pyrazol), 128.50/128.3/127.93 (5C, Ph),
105 (Ctert, C
20H, Pz), 61.57 (2C, 2OCH2CH3), 60.35 (Ctert,
PhC3HC2H), 57.52 (Ctert, Ph–C
3HC2H), 13.87 (C, C5
0
H3,
Pz), 13.67 (C, C3
0
H3, Pz), 13.64–10.06 (2C, 2OCH2CH3); SM
(IE): Calc. [M]+ C19H24N2O4: 344.17. Found [M+H]
+ (m/
z) = 345.28 (11%), 83 (100%); Element. analysis: Calc.
C19H24N2O4: %C= 66.27; %H= 6.97; %N= 8.13. Found:
%C= 65.71; %H= 5.80; %N= 8.78.
4.3.4. 2-[(Phenyl)-3,5-dimethyl-pyrazol-1-yl -methyl]-malonic
sodium (160)
White powder; Yield: 95%; Rf = 0 (ether/hexane: 1/1);
mp > 260 C; IR (KBr, m cm1): 2900 (CH); 1583 (C‚O),
1497 (C‚C), 1455 (C‚N), 1326–1250 (C–O); 1H NMR
(300 MHz, D2O) d ppm: 7.15–7.32 (m, 5H, Ph), 5.68 (d, 1H,
Ph–C3H, 3J= 11.2 Hz), 5.72 (s, 1H, H2
0
, Pz), 4.23 (d, 1H,
PhC3HC2H, 3J= 11.4 Hz), 1.99 (s, 1H, C1
0
H, Pz), 2.25 (s,
1H, C3
0
H, Pz); 13C NMR (300 MHz, D2O) d ppm: 175.57
(C‚O), 175.29 (C‚O), 148.51 (Cquat, C
10, Pz), 141.10 (Cquat,Ph), 138.86 (Cquat, C
30, Pz), 128.65 (Cmeta, 2H, Ph), 127.92
(Cortho, 2H, Ph), 127.43 (Cpara, 1H, Ph), 104.72 (Ctert, C
20H,
Pz), 62.95 (Ctert, PhC









White powder; Yield: 83%; mp: 154 C; Rf = 0.22 (ether/hex-
ane: 1/1); IR (KBr, m cm1): 2918–3068 (CH), 1705 (C‚O),
1555–1500 (C‚C), 1459–1484 (C‚N), 3406 (OH), 1343–
1273 (C–O), 1146, 104, 951; 1H NMR (300 MHz, acetone) d
ppm: 7.27–7.44 (m, 5H, Ph), 5.89 (d, 1H, Ph–C3H,
3J= 11.2 Hz), 5.83 (s, 1H, H2
0
, Pz), 4.78 (d, 1H, PhC3HC2H,




H, Pz); 13C NMR (300 MHz, acetone) d ppm: 167.07
(C‚O), 167.43 (C‚O), 146.73 (Cquat, C
10, pyrazol), 140.73
(Cquat, Ph), 139.96 (Cquat, C
30, Pz), 127.58–130.35 (Ctert,
5CH, Ph), 105.15 (Ctert, C
20H, pyrazol), 59.75 (Ctert,
PhC3HC2H), 57.75 (Ctert, Ph–C
3HC2H), 12.72 (C, C1
0
H3,
Pz), 10.08 (C, C3
0
H3, Pz).
4.3.6. 2-[(Phenyl)-dibenzyl amino-1-yl-methyl]-malonic acid
diethyl ester (17)
White crystals; Yield: 76%; Rf = 0.53 (ether/hexane: 1/1); mp:
119 C; IR (KBr, m cm1): 2883–2930 (C–H), 1747 (C‚O),
1584–1600 (C‚C), 1323–1252 (C–O), 1157, 1110, 1037; 1H
NMR (300 MHz, CDCl3) d ppm: 7.23–7.45 (m, 15H, arom),
4.59 (d, 1H, PhC3H, 3J= 12.0 Hz), 4.44 (d, 1H, C2H(CO2Et)2,
3J= 12.0 Hz), 3 (d, 2H, CH2Ph,
3J= 13.5 Hz), 3.98 (d, 2H,
CH2Ph,
3J= 13.5 Hz), 3.94 (dq, 2HAB,
2JAB = 14.29 Hz,
3J= 7.13 Hz), 4.22 (dq, 2HAB, JAB = 14.29 Hz,
3J= 7.13 Hz), 1.28 (t, 3H, OCH2CH3,
3J= 7.11 Hz), 0.95
(t, 3H, OCH2CH3,
3J= 7.11 Hz); 13C NMR (300 MHz,
CDCl3) d ppm: 167.51–166.86 (2C‚O), 139.05 (Cquat, C,
Ph), 133.79 (2Cquat, 2Ph), 129.27–127.0 (Ctert, Ph), 61.79 (Ctert,
C3H–Ph), 61.60 (C, OCH2CH3, ester), 61.13 (C, OCH2CH3,
ester), 55.39 (Ctert, C
2H(CO2Et)2), 53.94 (2Csec, 2CH2N),
13.92–13.65 (2C, 2OCH2CH3); SM (IE): Calc. [M]
+
C28H31NO4: 445.55. Found [M+H]
+ (m/z) = 446;
[MCH(CO2Et)2]+ (m/z) = 286 (100%); Element. analysis:
Calc. C28H31NO4: %C= 75.48; %H= 7.01; %N= 3.14.
Found: %C= 75.46; %H= 7.02; %N= 3.12.
4.3.7. 2-[(Phenyl)-benzyl methyl-1-yl-methyl]-malonic acid
diethyl ester (18)
White crystals; Yield: 78%; Rf = 0.45 (ether/hexane: 1/1); mp:
107 C; IR (KBr, m cm1): 2860–2984 (C–H), 1745 (C‚O),
1216–1301 (C–O), 1584–1601 (C‚C), 1138, 1021; 1H NMR
(300 MHz, CDCl3) d ppm: 1.01 (t, 3H, OCH2CH3,
3J= 7.2 Hz), 1.33 (t, 3H, OCH2CH3,
3J= 7.2 Hz), 3.25 (d,
1H, CH2Ph,
3J= 13.5 Hz), 3.5 (d, 1H, CH2Ph,
3J= 13.2 Hz), 4.32 (d, H, C2H(CO2Et)2,
3J= 12.20 Hz),
4.65 (d, H, Ph–C3H, 3J= 12.15 Hz), 4.01 (dq, 2HAB,
OCH2CH3,
2JAB = 14.34 Hz,
3J= 7.06 Hz), 4.35 (dq, 2HAB,
OCH2CH3,
2JAB = 14.34 Hz,
3J= 7.06 Hz), 2.05 (s, 3H,
CH3N), 7.2–74 (m, 10H, Ph);
13C NMR (300 MHz, CDCl3)
d ppm: 167.93 (C‚O), 167.97 (C‚O), 133.4 (Cquat, C–(Ph)),
132.6 (Cquat, CPhCH2), 126.91–128.03 (Ctert, 10CH arom),
67.47 (Ctert, C
3HPh); 61.24–61.3 (2C, 2CH2CH3, ester), 55.39
(Ctert, C
2H–(CO2Et)), 58.70 (Csec, C
10H2N), 36.94 (Ctert,
CH3N), 14.15–13.73 (2C, 2OCH2CH3); SM (IE): Calc. [M]
+
C28H30NO4Cl: 369.45. Found [M+H]
+ (m/z) = 370;
Synthesis, characterization and coordination chemistry of substituted b-amino dicarbonyls 169[MCH(CO2Et)2]+ (m/z) = 159 (100%); Element. analysis:
Calc. C28H30NO4Cl: %C= 71.52; %H= 7.37; %N= 3.79.
Found: %C= 71.48; %H= 7.35; %N= 3.81.
4.3.8. 2-[(Benzyl-ethyl-amine)-phenyl)-methyl]-malonic acid
diethyl ester (19)
White crystals; Yield: 82%; Rf = 0.51 (ether/hexane: 1/1); mp:
92 C; IR (KBr, m cm1): 2872–2935 (CH), 1731 (C‚O), 1490–
1594 (C‚C), 1290–1303 (C–O), 1179, 1012; 1H NMR
(300 MHz, CDCl3) d ppm: 7.18–7.38 (m, 10H, 2Ph), 4.65 (d,
1H, PhC3H, 3J= 12.1 Hz), 4.42 (d, 1H, C2H(CO2Et)2,
3J= 12.0 Hz), 3.98 (d, 1H, CH2Ph,
3J= 13.80 Hz), 2.95 (d,
1H, NCH2CH3,
3J= 13.80 Hz), 2.1 (dq, 1HAB, NCH2CH3,
JAB = 12.94 Hz,
3J= 7.2 Hz), 2.55 (dq, 1HAB, NCH2Ph,
2JAB = 12.94 Hz,
3J= 7.2 Hz), 4.0 (dq, 2HAB, OCH2CH3,
JAB = 14.1 Hz,
3J= 7.0 Hz), 4.3 (dq, 2HAB, OCH2CH3,
2JAB = 14.1 Hz,
3J= 7.0 Hz), 1.04 (t, 3H, NCH2CH3,
3J= 7.2 Hz), 1.1 (t, 3H, OCH2CH3,
3J= 7.2 Hz), 1.45 (t,
3H, OCH2CH3,
3J= 7.2 Hz); 13C NMR (300 MHz, CDCl3)
d ppm: 166.91–167.47 (2C‚O), 139.42 (Cquat, C–, Ph),
133.06 (Cquat, CH2Ph), 126.91–130.19 (Ctert, 2Ph), 61.32–
61.60 (Csec, 2OCH2CH3), 61.83 (Ctert, C
3HPh), 55.50 (Ctert,
C2H(CO2Et)2), 43.41 (Csec, NCH2CH3), 55.32 (Csec,
NCH2Ph), 13.40 (Ctert, NCH2CH3), 13.77 (Ctert, OCH2CH3),
14.06 (Ctert, OCH2CH3); SM (IE): Calc. [M]
+ C23H29NO4:
383.16. Found [M+H]+ (m/z) = 384; [MCH(CO2Et)2]+
(m/z) = 224 (100%); Element. analysis: Calc. C23H29NO4:
%C= 72.04; %H= 7.63; %N= 3.65. Found: %C= 72.0;
%H= 7.63; %N= 3.64.
4.3.9. 2-[(4-Chlorophenyl)-morpholin-4-yl-methyl]-malonic
acid diethyl ester (20)
White crystals; Yield: 96%; Rf = 0.55 (ether/hexane: 1/1); mp:
68–69 C; IR (KBr, m cm1): 2935–2985 (C–H, 4-Cl–Ph), 2826–
2887 (C–H), 1747 (C‚O), 1712 (C‚O), 1590–1489 (C‚C),
1306–1258 (C–O); 1H NMR (300 MHz, CDCl3) d ppm: 7.35
(d, 2H, ortho, 3J= 8.30 Hz), 7.12 (d, 2H, meta,
3J= 8.30 Hz), 4.25–4.39 (m, 3H, OCH2CH3 + PhC
3H), 4.20
(d, 1H, C2H (CO2Et)2,
3J= 10.3 Hz), 3.90–4.07 (m, 2H,
OCH2CH3), 3.93 (s, 4H, C
20H2OC
20H2), 2.53 (s, 2H, C
10H2),
2.30 (s, 2H, C1
0
H2), 1.06 (t, 3H, OCH2CH3,
3J= 7.1 Hz),
1.06 (t, 3H, OCH2CH3,
3J= 7.1 Hz); 13C NMR (300 MHz,
CDCl3) d ppm: 167.6 (2C‚O), 134.8 (Cquat, p-CCl, Ph),
131.8 (Cquat, Ph, para/Cl), 130 (Ctert, 2C-ortho, Ph), 128.4




H2O, mor), 61.6 (C, OCH2CH3), 61.5 (C, OCH2CH3),
54.6 (Ctert, C
2H(CO2Et)2), 49.5 (2C, 2C
10H2N, mor), 14.3 (C,
OCH2CH3), 13.8 (C, OCH2CH3); SM (IE): Calc. [M]
+
C18H24ClNO5: 369.13. Found [M+H]
+ (m/z) = 370 (15%);
[MCH(CO2Et)2]+ (m/z) = 210 (100%); Element. analysis:
Calc. C18H24NO5Cl: %C= 58.53; %H= 6.50; %N= 3.79.
Found: %C= 58.60; %H= 6.71; %N= 4.03.
4.3.10. 2-[(4-Chlorophenyl)-pyrrolidin-1-yl-methyl]-malonic
acid diethyl ester (21)
White crystals; Yield: 73%; Rf = 0.68 (ether/hexane: 1/1); mp:
79 C; IR (KBr, m cm1): 2969 (C–H, Ph), 2674–2806 (C–H),
1747–1720 (C‚O), 1592–1464 (C‚C), 1329–1256 (C–O); 1H
NMR (300 MHz, CDCl3) d ppm: 7.29–7.29 (m, 2H,Ph),
7.14–7.18 (m, 2H, Ph), 4.5 (d, 1H, PhC3H, 3J= 11.40 Hz),
4.09 (d, 1H, C2H(CO2Et)2,
3J= 11.40 Hz), 4.25 (q, 2H,
OCH2CH3,
3J= 7.1 Hz), 3.95 (m, 2H, OCH2CH3), 2.49 (m,2H, N–C1
0
H2, pyr), 2.35 (m, 2H, NC




20H2, pyr), 1.30 (t, 3H, OCH2CH3,
3J= 7.1 Hz),
1.03 (t, 3H, OCH2CH3,
3J= 7.1 Hz); 13C NMR (300 MHz,
CDCl3) d ppm: 166.97–167.88 (2C‚O), 133.35 (Cquat, CCl,
Ph), 133.22 (Cquat, Ph, para/Cl), 130.35 (Ctert, 2Cortho, Ph),
128.05 (Ctert, 2Cmeta, Ph), 64.05 (Ctert, C
3HPh), 61.40 (C,




H2N, pyr), 22.84 (2C, 2C
10H2C
20H2),
pyr), 13.91–14.12 (2C, 2OCH2CH3); SM (IE): Calc. [M]
+
C18H24ClNO4: 353.14. Found [M+H]
+ (m/z) = 354 (18%);
[MCH(CO2Et)2]+ (m/z) = 194 (100%); [Mpyrol]+ (m/z)
= 283; Element. analysis: Calc. C18H24ClNO4: %C= 62.12;




White crystals; Yield: 71%; Rf = 0.65 (ether/hexane; 1/1); mp:
89 C; IR (KBr, m cm1): 2896–2985 (CH), 1748 (C‚O), 1514–
1595 (C‚C), 1292–1308 (C–O); 1H NMR (300 MHz, CDCl3)
d ppm: 7.28–7.44 (m, 4H, Ph, 3J= 8.68 Hz), 6.20 (t, 1H, Pz,
3J= 2.08 Hz), 7.5 (d, 2H, C3
0
H, C5H, Pz, 3J= 14.27 Hz),
5.85 (d, 1H, PhC3H, 3J= 11.33 Hz), 4.80 (d, 1H,
C2H(CO2Et)2,
3J= 11.33 Hz), 4.10 (dq, 2HAB, OCH2CH3,
JAB = 14.32 Hz,
3J= 7.11 Hz), 4.01 (dq, 2HAB, OCH2CH3,
JAB = 14.32 Hz,
3J= 7.11 Hz), 2.25 (s, 3H, CH3, Pz), 2.20
(s, 3H, CH3, Pz), 1.13 (t, 3H, OCH2CH3,
3J= 7.11 Hz), 1.04
(t, 3H, OCH2CH3,
3J= 7.11 Hz); 13C NMR (300 MHz,
CDCl3) d ppm: 166.36 (C‚O), 166.26 (C‚O), 147.65 (Cquat,
Pz), 139.3 (Cquat, Pz), 135.7 (Cquat, CCl, Ph), 134.62 (Cquat,
Ph, para/Cl), 129.83 (Ctert, 2Cmeta/bras, Ph), 128.7 (Ctert,
2Cortho/bras, Ph), 129.27 (Ctert, C
30, Pz), 105.45 (Ctert, C
40H,
Pz), 61.75–61.70 (Csec, 2OCH2CH), 59.55 (Ctert, C
3HPh),
57.45 (Ctert, C
2H(CO2Et)2), 13.87 (C, OCH2CH3), 13.75 (C,
OCH2CH3), 13.66 (C, CH3, Pz), 10.95 (CH3, Pz); SM (IE):
Calc. [M]+ C17H19N2O4Cl: 350.5. Found [M+H]
+ (m/z)
= 351 (15%); [MCH(CO2Et)2]+ (m/z) = 191 (100%);
[MPz] + (m/z) = 283 (21%); Element. analysis: Calc.
C18H24ClNO4: %C= 64.55; %H= 6.32; %N= 8.86.
Found: %C= 64.46; %H= 6.62; %N= 9.06.
4.3.12. 2-[(4-Chlorophenyl)-piperidin-1-yl-methyl]-malonic
acid diethyl ester (23)
White crystals; Yield: 67%; Rf = 0.65 (ether/hexane: 1/1); mp:
65 C; IR (KBr, m cm1): 1755–1737 (C‚O), 2973–2848 (C–
H), 1493–1452 (C‚C), 1312–1257 (C–O); 1H NMR
(300 MHz, CDCl3) d ppm: 1.05 (t, 3H, OCH2CH3,
3J= 7.10 Hz), 1.26 (m, 2H, C3
0
H2,
3J= 5.9 Hz), 1.35 (t, 3H,
OCH2CH3,





H2), 2.46 (m, 2H, NC
10H2), 4.16 (d, H, C
2H(CO2Et)2,
3J= 12.10 Hz), 4.35 (d, H, PhC3H, 3J= 12.20 Hz), 4.02 (dq,
2HAB, OCH2CH3, JAB = 11.3 Hz), 4.30 (dq, 2HAB,
OCH2CH3, JAB = 10.7 Hz), 7.1 (d, 2H, arom-ortho,
3J= 10.7 Hz), 7.32 (d, 2H, arom-meta, 3J= 10.9 Hz); 13C
NMR (300 MHz, CDCl3) d ppm: 167.71 (C‚O), 167.03
(C‚O), 133.4 (Cquat, ClCPh), 132.6 (Cquat, para/Cl), 129.9
(Ctert, 2Cmeta, Ph), 128.04 (Ctert, 2Cortho, Ph), 69.5 (Ctert,
C3HPh), 61.4–61.3 (2C, 2OCH2CH3), 54.95 (Ctert,
C2H(CO2Et)), 50.51 (2C, 2C
10H2N), 26.4 (2C, 2C
20H2CH2N),
24.40 (C, N(CH2)2C
30H2), 14.3–13.8 (2C, 2OCH2CH3); SM
(IE): Calc. [M]+ C19H26ClNO4: 367.16. Found [M+H]
+
(m/z) = 368 (16%); [MCH(CO2Et)2]+ (m/z) = 256
170 I. Meskini et al.(100%); [MPhCl]+ (m/z) = 249; Element. analysis: Calc.
C19H26ClNO4: %C= 62.12; %H= 7.08; %N= 3.18.
Found: %C= 62.10; %H= 7.28; %N= 3.14.
4.3.13. 2-[(4-Chlorophenyl)-benzylethylamino-methyl]-malonic
acid diethyl ester (24)
White crystal; Yield: 84%; Rf = 0.56 (ether/hexane: 1/1); mp:
70–72 C; IR (KBr, m cm1): 2808–2985 (CH), 1732 (C‚O),
1594–1595 (C‚C), 1248–1291 (C–O); 1H NMR (300 MHz,
CDCl3) d ppm: 7.24–7.37 (m, 4H, PhCl,
3J= 8.43 Hz), 7.23–
7.1 (m, 5H, Ph, 3J= 4.42 Hz), 4.62 (d, 1H, ClPhC3H,
3J= 12.30 Hz), 4.24 (d, 1H, C2H(CO2Et)2,
3J= 12.30 Hz),
2.9 (d, 1H, CH–Ph, 3J= 13.80 Hz), 3.9 (d, 1H, CH–Ph, 3J
= 13.80 Hz), 2.1 (m, 1H, CHCH3,
3J= 12.90 Hz), 2.55 (m,
1H, CHCH3,
3J= 12.90 Hz), 4.01 (dq, 2HA–B, OCH2CH3,
JAB = 14.10 Hz,
3J= 7.07 Hz), 4.30 (dq, 2HAB, OCH2CH3,
JAB = 14.10 Hz,
3J= 7.07 Hz), 1.15 (t, 3H, NCH2–CH3),
1.30 (t, 3H, OCH2–CH3,
3J= 7.07 Hz), 1.01 (t, 3H,
OCH2CH3,
3J= 7.07 Hz); 13C NMR (300 MHz, CDCl3) d
ppm: 166.93 (C‚O), 167.84 (C–O), 139.41 (Cquat, CCl, Ph),
133.54 (Cquat, Ph, para/Cl), 130.81 (Ctert, 2Cmeta, Ph–Cl),
128.15 (Ctert, 2Cortho, Ph–Cl), 128.28 (Ctert, 2Cmeta, Ph),
128.15 (Ctert, 2Cortho, Ph), 126.91 (Ctert, 2Cpara, Ph), 61.75–
61.70 (Csec, 2OCH2CH3), 61.75 (Ctert, C
3HPhCl), 55.47 (Ctert,
C2H(CO2Et)2), 14.07 (Ctert, 2OCH2CH3), 13.79 (Ctert,
OCH2CH3), 13.41 (Ctert, NCH2CH3), 54.21 (Csec, NCH2CH3);
SM (IE): Calc. [M]+ C23H28ClNO4: 417.5; [M+H]
+ (m/z)
= 418 (12%). Found [MCH(CO2Et)2]+ (m/z) = 258
(100%); [MN(CH2Ph,C2H5)]+ (m/z) = 283; Element. analy-
sis: Calc. C23H28ClNO4: %C= 66.18; %H= 6.71; %N=
3.35. Found: %C= 65.53; %H= 6.66; %N= 3.55.
4.3.14. 2-[(4-Chlorophenyl)-3,5-dimethyl-pyrazol-1-yl-methyl]-
malonic acid diethyl ester (25)
White crystals; Yield: 83%; Rf = 0.67 (ether/hexane: 1/1); mp:
83 C; IR (KBr, m cm1): 2981–2935 (CH), 1764 (C‚O), 1594–
1554 (C‚C), 1490–1463 (C‚N), 1300–1257 (C–O); 1H NMR
(300 MHz, CDCl3) d ppm: 7.25–7.44 (m, 4H, Ph,
3J= 8.25 Hz), 5.74 (s, 1H, Pz), 5.70 (d, 1H, PhC3H,
3J= 11.3 Hz), 4.84 (d, 1H, C2H(CO2Et)2,
3J= 11.3 Hz),
4.12 (dq, 2HAB, OCH2CH3, JAB = 14.3 Hz,
3J= 7.2 Hz),
4.0 (dq, 2HAB, OCH2CH3, JAB = 14.3 Hz,
3J= 7.2 Hz),
2.25 (s, 3H, CH3, Pz), 2.20 (s, 3H, CH3, Pz), 5.75 (s, 1H, C
40,
Pz), 1.16 (t, 3H, OCH2CH3,
3J= 7.1 Hz), 1.04 (t, 3H,
OCH2CH3,
3J= 7.1 Hz); 13C NMR (300 MHz, CDCl3) d
ppm: 166.60 (C‚O), 166.75 (C‚O), 147.65 (Cquat, Pz),
139.3 (Cquat, Pz), 138.9 (Cquat, CCl, Ph), 134.25 (Cquat, Ph,
para/Cl), 129.4 (Ctert, 2Cmeta, Ph), 128.7 (Ctert, 2Cortho, Ph),
105.45 (Ctert, CH, Pz), 61.75–61.70 (Csec, 2OCH2CH3), 59.55
(Ctert, C
3HPh), 57.45 (Ctert, C
2H(CO2Et)2), 13.87 (Ctert,
OCH2CH3), 13.75 (Ctert, OCH2CH3), 13.66 (Ctert, CH3, Pz),
10.95 (Ctert, CH3, Pz); MS (IE): Calc. [M]
+ C19H23ClN2O4:
378.13. Found [M+H]+ (m/z) = 379 (17%);
[MCH(CO2Et)2]+ (m/z) = 219 (100%); [MPz)]+ (m/z)
= 283; Element. analysis: Calc. C19H23ClN2O4: %C=
60.31; %H= 6.08; %N= 7.40. Found: %C= 60.43; %H
= 6.05; %N= 7.69.
4.3.15. 2-[(4-Chlorophenyl)-dibenzyl amino-1-yl-methyl]-
malonic acid diethyl ester (26)
White crystals; Yield: 67%; Rf = 0.42 (ether/hexane: 1/1); mp:
112 C; IR (KBr, m cm1): 2811–2980 (CH); 1722 (CO), 1591(C‚C), 1257–1301 (C–O), 1181, 1092, 822, 747, 416; 1H
NMR (300 MHz, CDCl3) d ppm: 7.24–7.44 (m, 4H, arom,
Ph–Cl, 3J= 6.60 Hz), 7.23–7.31 (m, 10H, arom, Ph,
3J= 4.15 Hz), 4.56 (d, 1H, ClPhC3H, 3J= 12.12 Hz), 4.33
(d, 1H, C2H(CO2Et)2,
3J= 12.12 Hz), 3.0 (d, 1H, 2CHPh,
3J= 13.50 Hz), 3.9 (d, 1H, 2CHPh, 3J= 13 Hz), 3.98 (dq,
2HAB, OCH2CH3,
2JAB = 14.10 Hz,
3J= 7.10 Hz), 4.20–
4.40 (dq, 2HAB, OCH2CH3,
2JAB = 14.11 Hz,
3J= 7.10 Hz),
1.30 (t, 3H, OCH2CH3,
3J= 7.10 Hz), 1.01 (t, 3H, OCH2CH3,
3J= 7.10 Hz), 1.25 (t, 3H, OCH2CH3,
3J= 7.10 Hz); 13C
NMR (300 MHz, CDCl3) d ppm: 166.74–167.26 (2C‚O),
138.71 (Cquat, CCl, Ph), 133.68 (Cquat, p-Cl–Ph), 130.47 (Ctert,
2Cmeta, p-Cl–Ph), 128.91 (Ctert, 2Cortho, p-Cl–Ph), 128.29
(Cquat, 2C, 2Ph), 128.34 (Ctert, 4Cmeta, 2Ph), 128.29 (Ctert,
4Cortho, 2Ph), 127.15 (Ctert, 2Cpara, 2Ph), 61.73 (Csec,
2OCH2CH3), 61.04 (Ctert, C
3HPhCl), 55.26 (Ctert,
C2H(CO2Et)2), 13.75 (Ctert, OCH2CH3), 13.92 (Ctert,
OCH2CH3), 61.31 (Csec, 2CH2Ph); SM (IE): Calc. [M]
+
C28H30NO4Cl: 479.99. Found [M+H]
+ (m/z) = 481;
[MCH(CO2Et)2]+ (m/z) = 320 (100%); Element. analysis:
Calc. C28H30NO4Cl: %C = 70.06; %H= 6.30; %N= 2.92.
Found: %C= 69.98; %H= 6.27; %N= 2.91.
4.3.17. 2-[(4-Chlorophenyl)-4-bromo,3,5-dimethyl-pyrazol-1-
yl-methyl]-malonique acid diethyl (27)
White crystals; Yield: 86%; Rf = 0.53 (ether/hexane: 1/1); mp:
95 C; IR (KBr, m cm1): 2984–2939 (CH), 1758 (C‚O), 1595–
1543 (C‚C), 1490–1463 (C‚N), 1300–1265 (C–O); 1H NMR
(300 MHz, CDCl3) d ppm: 7.26–7.39 (m, 4H, Ph,
3J= 6.30 Hz), 5.78 (d, 1H, PhC3H, 3J= 11.3 Hz), 4.83 (d,
1H, C2H(CO2Et)2,
3J= 11.3 Hz), 4.20 (dq, 2HAB, OCH2CH3,
JAB = 13.54 Hz,
3J= 7.2 Hz), 4.0 (dq, 2HAB, OCH2CH3,
JAB = 13.54 Hz,
3J= 7.2 Hz), 2.24 (s, 3H, CH3, Pz), 2.18 (s,
3H, CH3, Pz), 1.13 (t, 3H, OCH2CH3,
3J= 7.2 Hz), 1.02 (t,
3H, OCH2CH3,
3J= 7.2 Hz); 13C NMR (300 MHz, CDCl3)
d ppm: 166.08 (C‚O), 167.01 (C‚O), 146.29 (Cquat, Pz),
137.5 (Cquat, Pz), 136.58 (Cquat, CCl, Ph), 134.35 (Cquat, Ph,
para/Cl), 127.88 (Ctert, 2Cmeta, Ph), 128.31 (Ctert, 2Cortho,
Ph), 94.83 (Cquat, C
4Br, Pz), 61.47–61.70 (Csec, 2OCH2CH3),
59.88 (Ctert, C
3HPh), 56.99 (Ctert, C
2H(CO2Et)2), 13.86
(OCH2CH3), 14.08 (OCH2CH3), 12.41(CH3, Pz), 11.26 (CH3,
Pz); MS (IE): Calc. [M]+ C19H22ClN2O4Br: 456. Found
[M+H]+ (m/z) = 457; [MCH(CO2Et)2]+ (m/z) = 297
(100%); [Mpyrazol)]+ (m/z) = 361.
4.3.18. 2-[(4-Triﬂoromethyl-phenyl)-pyrrolidin-1-yl-methyl]-
malonic acid diethyl ester (28)
White crystals; Yield: 73%; Rf = 0.62 (ether/hexane: 1/1); mp:
73 C; IR (KBr, m cm1): 2875–2940 (C–H), 1745 (C‚O),
1585–1618 (C‚C), 1269–1264 (C–O), 1153, 1112, 1066; 1H
NMR (300 MHz, CDCl3) d ppm: 7.33 (d, 2Hortho,
3J= 8.03 Hz), 7.60 (d, 2Hmeta,
3J= 8.03 Hz), 4.6 (d, 1H,
Ph–C3H, 3J= 11.25 Hz), 4.13 (d, 1H, PhC3HC2H,
3J= 11.25 Hz), 4.3 (dq, 2HAB, OCH2CH3,
2JAB = 10.08 Hz,
3J= 7.3 Hz), 4.0 (dq, 2HAB, OCH2CH3,
2JAB = 10.08 Hz,
3J= 7.3 Hz), 2.35 (s, 2H, C1
0
H2–pyr), 2.47 (s, 2H, C
10H2–
pyr), 1.6 (m, 4H, C2
0
H, pyr), 1.3 (t, 3H, OCH2CH3,
3J= 7.2 Hz); 1.6 (t, 3H, OCH2CH3,
3J= 7.2 Hz); 13C NMR
(300 MHz, CDCl3) d ppm: 166.89–167.75 (2C‚O), 138.95
(Cquat, CF3Ph), 129.0 (Cquat, p-CF3Ph), 128.11 (Ctert, Cmeta,
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20H, pyr), 22.84 (2Csec,
2C1
0
H, pyr), 13.66–14.03 (2Ctert, 2OCH2CH3); SM (IE): Calc.
[M]+ C19H24NO4F3: 387.39. Found [M+H]
+ (m/z) = 388;
[MCH(CO2Et)2]+ (m/z) = 228 (100%); Element. analysis:
Calc. C19H24NO4F: %C= 58.91; %H= 6.24; %N= 3.62.
Found: %C= 60.01; %H= 6.25; %N= 3.61.
4.3.19. 2-[(4-Triﬂoromethyl-phenyl)-piperidin-methyl]-malonic
acid diethyl (29)
White crystals; Yield: 67%; Rf = 0.67 (ether/hexane: 1/1); mp:
92 C; IR (KBr, m cm1): 2875–2938 (CH), 1729 (C‚O), 1491–
1593 (C‚C), 1291–1302 (C–O), 1180, 1011; 1H NMR
(300 MHz, CDCl3) d ppm: 1.03 (t, 3H, OCH2CH3,
3J= 7.2 Hz), 1.35 (t, 3H, OCH2CH3,
3J= 7.2 Hz), 1.26 (m,
2H, C3
0
H2, pip), 1.52 [m, 4H, 2(C
20H2), pip], 2.1 (s, 2H,
C1
0
H2, pip), 2.51 (s, 2H, C
10H2, pip), 4.01 (dq, 2HAB,
OCH2CH3,
2JAB = 10.14 Hz,
3J= 7.04 Hz), 4.22 (d, 1H,
C2H(CO2Et)2,
3J= 12.11 Hz), 4.30 (dq, 2H, OCH2CH3,
2JAB = 10.14 Hz,
3J= 7.02 Hz), 4.41 (d, 1H, PhC3H,
3J= 12.1 Hz), 7.27(d, 2Hortho,
3J= 8.1 Hz), 7.58 (d, 2Hmeta,
3J= 8.1 Hz); 13C NMR (300 MHz, CDCl3) d ppm: 166.97–
166 (2C‚O), 129.50 (Cquat, arom), 138.17 (Cquat, C–CF3);
129.05 (2Ctert, meta, Ph), 124.80 (Ctert, ortho, Ph), 54.74 [Ctert,
PhC2H(CO2Et)2], 68.63 (Ctert, PhC3
0
H), 61.45–61.35 (2C,
2OCH2CH3), 50.54 (2C, 2C
10H2, pip), 26.38 (2C, 2C
20H2,
pip), 24.27 (C, C3
0
H2, pip), 14.25–13.72 (2C, 2OCH2CH3);
SM (IE): Calc. [M]+ C20H26NO4F3: 401.41. Found
[M+H]+ (m/z) = 402; [MCH(CO2Et)2]+ (m/z) = 242
(100%); Element. analysis: Calc. C20H26NO4F3: %C=
59.84; %H= 6.53; %N= 3.49. Found: %C= 59.82;
%H= 6.51; %N= 3.47.
4.3.20. 2-[(4-Triﬂoromethyl-phenyl)-morpholin-methyl]-
malonic acid diethyl ester (30)
White crystals; Yield: 96%; Rf = 0.67 (ether/hexane: 1/1); mp:
103 C; IR (KBr, m cm1): 2870–2934 (CH), 1730 (C‚O),
1491–1593 (C‚C), 1291–1304 (C–O), 1181; 1014; 1H NMR
(300 MHz, CDCl3) d ppm: 1.33 (t, 3H, OCH2CH3,
3J= 7.2 Hz), 1.01 (t, 3H, OCH2CH3,
3J= 7.2 Hz), 3.54–
3.66 (m, 4H, C2
0
H2, mor), 2.29 (s large, 2H, C
10H2, mor),
2.53 (s large, 2H, C1
0
H2, mor), 4.0 (dq, 2HAB, OCH2CH3,
2JAB = 14.06 Hz,
3J= 7.01 Hz), 4.33 (dq, 2H, OCH2CH3,
2JAB = 14.06 Hz,
3J= 7.01 Hz), 4.25 (d, 1H, C2H(CO2Et)2,
3J= 12.13 Hz), 4.42 (d, 1H, PhC3H, 3J= 12.13 Hz), 7.64 (d,
2Hortho,
3J= 8.1 Hz), 7.28 (d, 2Hmeta,
3J= 8.1 Hz); 13C
NMR (300 MHz, CDCl3) d ppm: 166.62–167.42 (2C‚O),
130.40 (Cquat, Ph), 137.51 (Cquat, CCF3Ph), 125.08 (2Ctert,
meta-arom), 129.96 (Ctert, ortho-arom), 54.49 (Ctert,
PhC2H(CO2Et)2), 68.11 (Ctert, PhC
30H), 61.62–61.54 (2C,
2OCH2CH3), 49.52 (Csec, 2C
10H2, mor), 67.12 (Csec, 2C
20H2,
mor), 14.30–13.17 (Ctert, 2OCH2CH3); SM (IE): Calc. [M]
+
C19H24NO5F3: 403.39. Found [M+H]
+ (m/z) = 404;
[MCH(CO2Et)2]+ (m/z) = 244 (100%); Element. analysis:
Calc. C19H24NO5F3: %C= 56.57; %H= 6.00; %N= 3.47.
Found: %C= 56.54; %H= 5.97; %N= 3.45.
4.3.21. 2-[(4-Triﬂoromethyl-phenyl)-dibenzyl-methyl]-malonic
acid diethyl ester (31)
White crystals; Yield: 96%; Rf = 0.67 (ether/hexane: 1/1); mp:
104 C; IR (KBr, m cm1): 2841–2902 (CH), 1731 (2C‚O),
1585–1618 (C‚C), 1257–1306 (C–O), 1164; 1H NMR
(300 MHz, CDCl3) d ppm: 7.25–7.72 (m, 4H, arom, Ph–CF3,3J= 8.1 Hz), 7.35 (m, 10H, arom, Ph, 3J= 6 Hz), 4.63 (d,
1H, CF3PhC
3H, 3J= 12 Hz), 4.4 (d, 1H, –C2H(CO2Et)2,
3J= 12 Hz), 3.0 (d, 1H, 2CH–Ph, 3J= 13.50 Hz), 3.9 (d,
1H, 2CHPh, 3J= 13.62 Hz), 4.0 (dq, 2HAB, OCH2CH3,
JAB = 14.28 Hz,
3J= 7.15 Hz), 4.20–4.40 (dq, 2HAB,
OCH2CH3, JAB = 14.28 Hz,
3J= 7.15 Hz), 1.28 (t, 3H,
OCH2CH3,
3J= 7.11 Hz), 1.0 (t, 3H, OCH2CH3,
3J=
7.11 Hz); 13C NMR (300 MHz, CDCl3) d ppm: 166.66–
167.14 (2C‚O), 138.53 (Cquat, C–CF3–Ph), 138.09 (Cquat,
Ph, para/CF3), 128.17–125.01 (Ctert, arom), 130.22–129.43
(Cquat, 2C/arom, 2Ph), 61.78–61.37 (Csec, 2OCH2CH3), 61.28
(Ctert, C
3HPhCF3), 55.11 (Ctert, C
2H(CO2Et)2), 53.15–53.94
(Csec, 2CH2–Ph), 13.67 (Ctert, OCH2CH3), 13.91 (Ctert,
OCH2CH3); SM (IE): Calc. [M]
+ C19H24N1O5F3: 513.54.
Found [M+H]+ (m/z) = 514; [MCH(CO2Et)2]+ (m/z)
= 354 (100%); Element. analysis: Calc. C19H24N1O5F3: %C
= 67.82; %H= 5.89; %N= 2.73. Found: %C= 67.79;
%H= 5.87; %N= 2.72.
4.3.22. 2-[(3,5-Dimethyl-pyrazol-1-yl)-4-methylphenyl-
methyl]-malonic acid diethyl (32)
White crystals; Yield: 74%; Rf = 0.45 (ether/hexane: 1/1); mp:
88 C; IR (KBr, m cm1): 2872–2926 (C–H), 1752 (C‚O),
1514–1594 (C‚C), 1263–1305 (C–O), 1148, 1027; 1H NMR
(300 MHz, CDCl3) d ppm: 7.08 (d, 2Hortho,
3J= 7.88 Hz),
7.32 (d, 2Hmeta,
3J= 8.80 Hz), 5.72 (s, 1H, C4
0
, Pz), 5.75 (d,
1H, Ph–C3H, 3J= 11.31 Hz), 4.89 (d, 1H, C2H–(CO2Et)2,
3J= 11.31 Hz), 4.14 (dq, 2HAB, OCH2CH3,
2JAB = 14.37 Hz,
3J= 7.2 Hz), 3.97 (dq, 2HAB, OCH2CH3,
2JAB = 14.37 Hz,
3J= 7.2 Hz), 2.24 (s, 3H, CH3, Pz), 2.19 (s, 3H, CH3, Pz),
1.13 (t, 3H, OCH2CH3,
3J= 7.2 Hz), 0.98 (t, 3H, OCH2CH3,
3J= 7.2 Hz), 2.29 (s, 3H, CH3Ph);
13C NMR (300 MHz,
CDCl3) d ppm: 166.94 (2C‚O), 137.9 (Cquat, Pz), 144 (Cquat,
Pz), 132 (Cquat, CCH3, Ph), 130.05 (Cquat, para-CH3–Ph),
129.0 (Ctert, 2Cmeta, Ph), 127.77 (Ctert, 2Cortho, Ph), 105.20
(Ctert, C
40H, Pz), 61.55 (Csec, 2OCH2CH3), 60.05 (Ctert, C
3H–
Ph), 57.55 (Ctert, C
2H–(CO2Et)2), 13.8–13.70 (2Csec,
2OCH2CH3), 21.09 (Ctert, CH3–Ph), 10.97–12.20 (Ctert,
2CH3, Pz); SM (IE): Calc. [M]
+ C20H26N2O4 = 358.43.
Found [M+H]+, (m/z) = 359; [(M)CH(CO2Et)2]+ (m/
z) = 199 (100%); Element. analysis: Calc. C20H26N2O4:
%C= 67.02; %H= 7.31; %N= 7.82. Found: %C=
66.97; %H= 7.32; %N= 7.82.
4.3.23. 2-[(4-Methyl-phenyl)-piperidim-methyl]-malonic acid
diethyl (33)
White crystals; Yield: 67%; Rf = 0.67 (ether/hexane: 1/1); mp:
91 C; IR (KBr, m cm1): 2873–2935 (CH), 1734 (C‚O), 1493–
1592 (C‚C), 1289–1301 (C–O), 1180, 1013; 1H NMR
(300 MHz, CDCl3) d ppm: 1.32 (t, 3H, OCH2CH3,
3J= 7.2 Hz), 1.29 (t, 3H, OCH2CH3,
3J= 7.2 Hz), 1.26 (m,
2H, C3
0
H2, pip), 1.49 (m, 4H, 2C
20H2, pip), 2.18 (s, 2H,
C1
0
H2, pip), 2.5 (s, 2H, C
10H2, pip), 4.1 (dq, 2HAB, OCH2CH3,
2JAB = 9.74 Hz,
3J= 7.08 Hz), 4.30 (dq, 2H, OCH2CH3,
2JAB = 9.74 Hz,
3J= 7.08 Hz), 4.22 (d, 1H, C2H(CO2Et)2,
3J= 12.13 Hz), 4.35 (d, 1H, Ph–C3H, 3J= 12.13 Hz), 7.03
(d, 2Hortho,
3J= 8.82 Hz), 7.06 (d, 2Hmeta,
3J= 8.82 Hz),
2.25 (s, 3H, CH3–Ph);
13C NMR (3000 MHz, CDCl3) d ppm:
167.20–168.08 (2C‚O), 130.91 (Cquat, Ph), 137.05 (Cquat,
CCH3, Ph), 128.58 (2Ctert, meta, Ph), 58.50 (Ctert, ortho, Ph),
55.07 (Ctert, PhC
2H(CO2Et)2), 68.81 (Ctert, PhC
30H), 61.23–
61.09 (2C, 2OCH2CH3), 50.53 (C, 2C
10H2, pip), 26.46 (2C,
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0
H2, pip), 24.27 (C, C
30H2, pip), 14.28–13.77 (2C,
2OCH2CH3); SM (IE): Calc. [M]
+ C20H29N1O4: 347.44.
Found: [M+H]+ (m/z) = 348; [MCH(CO2Et)2]+ (m/
z) = 188 (100%); Element. analysis: Calc. C20H29N1O4:
%C= 69.14; %H= 8.41; %N= 4.03. Found:
%C= 69.05; %H= 8.39; %N= 4.01.
4.3.24. 2-[(3,5-Dimethyl-pyrazol-1-yl)-4-methoxylphenyl-
methyl]-malonic acid diethyl (34)
White crystals; Yield: 85%; Rf = 0.63 (ether/hexane: 1/1); mp:
89 C; IR (KBr, m cm1): 2834–2987 (C–H), 1732 (C‚O),
1534–15345 (C‚C), 1223–1317 (C–O), 1148, 1027; 1H NMR
(300 MHz, CDCl3) d ppm: 7.12 (d, 2Hortho,
3J= 7.88 Hz),
7.26 (d, 2Hmeta,
3J= 8.76 Hz), 5.67 (s, 1H, C4
0
, Pz), 5.78 (d,
1H, Ph–C3H, 3J= 11.32 Hz), 4.82 (d, 1H, C2H–(CO2Et)2,
3J= 11.32 Hz), 4.18 (dq, 2HAB, OCH2CH3,
2JAB = 14.29 Hz,
3J= 7.1 Hz), 3.98 (dq, 2HAB, OCH2CH3,
2JAB = 14.32 Hz,
3J= 7.1 Hz), 2.24 (s, 3H, CH3, Pz), 2.19 (s, 3H, CH3, Pz),
1.12 (t, 3H, OCH2CH3,
3J= 7.1 Hz), 1.03 (t, 3H, OCH2CH3,
3J= 7.1 Hz), 2.22 (s, 3H, CH3Ph);
13C NMR (300 MHz,
CDCl3) d ppm: 166.65 (2C‚O), 137.9 (Cquat, Pz), 144 (Cquat,
Pz), 136 (Cquat, COCH3, Ph), 130.05 (Cquat, pOCH3–Ph),
129.12 (Ctert, 2Cmeta, Ph), 127.73 (Ctert, 2Cortho, Ph), 105.20
(Ctert, C
40H, Pz), 61.55 (Csec, 2OCH2CH3), 60.02 (Ctert, C
3H–
Ph), 57.48 (Ctert, C
2H–(CO2Et)2), 13.8–13.70 (2Csec,
2OCH2CH3), 21.09 (Ctert, CH3–Ph), 11.23–12.13 (Ctert,
2CH3, Pz).
4.3.25. 2-[(3,5-Dimethyl-pyrazol-1-yl)-4-methoxylphenyl-
methyl]-malonic acid diethyl (35)
White crystals; Yield: 81%; Rf = 0.65 (ether/hexane: 1/1); mp:
92 C; IR (KBr, m cm1): 2823–2898 (C–H), 1752 (C‚O),
1534–1554 (C‚C), 1254–1319 (C–O), 1148, 1027; 1H NMR
(300 MHz, CDCl3) d ppm: 7.17 (d, 2Hortho,
3J= 7.67 Hz),
7.28 (d, 2Hmeta,
3J= 8.67 Hz), 5.68 (s, 1H, C4
0
, Pz), 5.74 (d,
1H, Ph–C3H, 3J= 11.3 Hz), 4.83 (d, 1H, C2H–(CO2Et)2,
3J= 11.3 Hz), 4.12 (dq, 2HAB, OCH2CH3,
2JAB = 14.28 Hz,
3J= 7.2 Hz), 3.97 (dq, 2HAB, OCH2CH3,
2JAB = 14.28 Hz,
3J= 7.2 Hz), 2.24 (s, 3H, CH3, Pz), 2.19 (s, 3H, CH3, Pz),
1.13 (t, 3H, OCH2CH3,
3J= 7.2 Hz), 1.00 (t, 3H, OCH2CH3,
3J= 7.2 Hz), 2.29 (s, 3H, CH3Ph);
13C NMR (300 MHz,
CDCl3) d ppm: 167.13 (2C‚O), 137.9 (Cquat, Pz), 144 (Cquat,
Pz), 130.05 (Cquat, para-NO2–Ph), 129.01 (Ctert, 2Cmeta, Ph),
127.77 (Ctert, 2Cortho, Ph), 105.20 (Ctert, C
40H, Pz), 61.55 (Csec,
2OCH2CH3), 60.05 (Ctert, C
3H–Ph), 57.55 (Ctert, C
2H–
(CO2Et)2), 13.8–13.70 (2Csec, 2OCH2CH3), 21.09 (Ctert, CH3–
Ph), 10.97–12.20 (Ctert, 2CH3, Pz).
4.3.26. Synthesis of complex [Cu2(CH3COO
)4(H2O)2] (36)
The KOH (0.058 g; 1.05 mmol) was added to a solution of 2-
[(4-chlorophenyl)-3,5-dimethyl-pyrazol-1-yl-methyl]-malonic
acid diethyl (25) (0.2 g; 0.52 mmol) in ethanol (15 mL) and the
stirring was continued under reﬂux in ethanol (4 h), until the
complete saponiﬁcation of the starting material. After addition
of Cu(NO3)Æ3H2O, the color changed from blue to purple. The
stirring was further continued for additional 6 h. The organic
solvent was evaporated slowly over a period of 2 days to give
a pure paramagnetic compound as purple crystals (36). Purple
crystals; Yield: 55%; Decomposition > 260 C; IR (KBr, m
cm1): 2934–2988 (CH), 1595 (C‚O), 1416 (C‚O), 3269–
3466 (OH, H2O), 1354, 1092, 830. The ORTEP view of (36)
is given in Fig. 3.5. Conclusion
In spite of having prolonged reaction time, this aza-Michael
addition protocol led to higher yields in an aqueous medium
at room temperature, and consequently, would appear to be
a simple and useful synthetic protocol. Considering its high
efﬁciency to run at gram-scale level and especially high purity
of the ﬁnal products, this protocol is thus of great usefulness
for the synthesis of potentially new drug candidates. The X-
ray crystal structures of (17) and (24) were studied ﬁrst time
and found in complete agreement with the proposed one than
in solution.
6. Supplementary data
Supplementary crystallographic data for the reported com-
pounds (17) and (24) are available from the CCDC, 12 Union-
Road, Cambridge CB2 1EZ, UK on request, quoting the
deposition number CCDC 734201 and CCDC 734199.Acknowledgement
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